Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(2-thienylmethyl)-2,5-thiophenedisulfonamide is a synthetic small molecule featuring a thiophene ring substituted with sulfonamide groups at the 2 and 5 positions and an N-linked thienylmethyl group. It has been studied primarily as a potent inhibitor of carbonic anhydrase enzymes, particularly carbonic anhydrase II. The compound exhibits high binding affinity (Kd ~0.83 nM) for this target[4]. Its structure makes it of interest in medicinal chemistry for the development of enzyme inhibitors and potential pharmaceutical agents targeting diseases where carbonic anhydrase activity is implicated[4][7]. There are no known approved clinical uses or marketed products containing this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(2-thienylmethyl)-2,5-thiophenedisulfonamide.